---
schema_version: "secwatch.filing_event.v1"
accession: "0001636282-26-000105"
form_type: "8-K"
ticker: "SYRE"
cik: "0001636282"
company_name: "Spyre Therapeutics, Inc."
filed_at: "2026-08-25T20:04:39+00:00"
generated_at: "2026-08-25T20:06:45.330773+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Spyre SPY072 RA sub-study shows significant efficacy vs placebo but misses bar for RA monotherapy

## Summary
- SPY072 Low Dose ΔDAS28-CRP -1.9 (p<0.05) vs placebo -1.3 at Week 12; High Dose ACR20 63% (nominal p<0.05) vs placebo 43%.
- Low Dose ACR50 38% (nominal p<0.05) vs placebo 19%; ACR70 4% vs 2%.
- Adverse events 27% active vs 36% placebo; one serious TEAE per arm, none drug-related; one death in placebo arm.
- Did not meet internal bar to prioritize SPY072 as monotherapy in RA; supports TL1A combo potential.
- PsA/axSpA topline on track Q4 2026; SPY072 + IL-17A/F HS readout late 2027/early 2028.

## SEC filing metadata
- accession: 0001636282-26-000105
- form_type: 8-K
- ticker: SYRE
- cik: 0001636282
- company_name: Spyre Therapeutics, Inc.
- filed_at: 2026-08-25T20:04:39+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1636282/000163628226000105/0001636282-26-000105-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1636282/000163628226000105/syre-20260825.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001636282-26-000105
- JSON: https://secwatch.observer/filing/0001636282-26-000105.json
- Plain text: https://secwatch.observer/filing/0001636282-26-000105.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.